GlaxoSmithKline | GSK - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.8B 411M 2026-09
Alcon AG USD 1.68B 16M 2026-06
Almirall EUR 429.87M 180.02M 2025-12
Amgen USD 8.46B 1.22B 2026-09
argenx SE USD 1.56B 186M 2026-09
AstraZeneca USD 13.28B 421M 2026-09
Bayer EUR 6.33B 1.84B 2026-06
Biogen USD 2.25B 127.8M 2026-09
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Eli Lilly USD 20.59B 886M 2026-09
Fresenius EUR 1.55B 16M 2026-06
Fresenius Medical Care EUR 1.28B 33.98M 2026-09
Genmab DKK 1.07B 240M 2026-06
Gilead Sciences USD 6.73B 74M 2026-09
GlaxoSmithKline GBP 6.51B 757M 2026-06
Glaxosmithkline GBP 6.5B 743M 2026-09
GRIFOLS EUR 704M 84M 2026-06
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Lakefront Biotherapeutics EUR 1.68M 898.68M 2026-03
Lonza CHF 1.29B 248M 2025-06
Merck EUR 3.17B 101M 2026-06
Merck USD 12.21B 121M 2026-06
Novartis USD 11.42B 180M 2026-09
Novo Nordisk DKK 64.01B 1.19B 2025-06
Orion EUR 365.5M 25.6M 2026-09
Pfizer USD 3.24B 3.49B 2026-09
Philips EUR 2.04B 110M 2026-09
Recordati EUR 497.97M 12.85M 2026-06
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 11.7B 2.99B 2026-09
Smith & Nephew USD 2.09B 117M 2025-12
UCB EUR 3.19B 621M 2025-12